Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 7
1984 11
1985 22
1986 43
1987 90
1988 84
1989 102
1990 99
1991 87
1992 92
1993 88
1994 113
1995 97
1996 73
1997 56
1998 75
1999 66
2000 56
2001 45
2002 62
2003 55
2004 49
2005 82
2006 59
2007 62
2008 66
2009 58
2010 59
2011 56
2012 66
2013 60
2014 67
2015 67
2016 39
2017 49
2018 44
2019 42
2020 76
2021 99
2022 72
2023 72
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

2,519 results

Results by year

Filters applied: . Clear all
Page 1
Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm.
Yang H, George SJ, Thompson DA, Silverman HA, Tsaava T, Tynan A, Pavlov VA, Chang EH, Andersson U, Brines M, Chavan SS, Tracey KJ. Yang H, et al. Mol Med. 2022 May 16;28(1):57. doi: 10.1186/s10020-022-00483-8. Mol Med. 2022. PMID: 35578169 Free PMC article.
The effects of ICV famotidine were significantly more potent as compared to the peripheral route. ...Either bilateral sub-diaphragmatic vagotomy or genetic knock-out of alpha7nAChR abolished the anti-inflammatory effects of famotidine, indicating the inflammatory re …
The effects of ICV famotidine were significantly more potent as compared to the peripheral route. ...Either bilateral sub-diaphragmat …
Clinical pharmacokinetics of famotidine.
Echizen H, Ishizaki T. Echizen H, et al. Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. Clin Pharmacokinet. 1991. PMID: 1764869 Review.
Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. ...Coadministration of potent antacids reduces the oral absorption of famotidine by 20 to 30%. On a weight-to-weight basis, the antisecretory
Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. ...Coadm
Famotidine in the management of schizophrenia.
Martinez MC. Martinez MC. Ann Pharmacother. 1999 Jun;33(6):742-7. doi: 10.1345/aph.18262. Ann Pharmacother. 1999. PMID: 10410190 Review.
Key search terms included famotidine, schizophrenia, and histamine. DATA SYNTHESIS: Schizophrenia is a complicated disorder associated with high morbidity if left unmanaged. ...CONCLUSIONS: Famotidine can improve schizophrenic symptoms that were otherwise refractory …
Key search terms included famotidine, schizophrenia, and histamine. DATA SYNTHESIS: Schizophrenia is a complicated disorder associate …
Therapeutic Status of Famotidine in COVID-19 Patients: A Review.
Mohseni M, Raissi V, Sharifan Y, Barikro K, Amiri S, Mohseni MS, Raeisi F, Masoumi K, Khodakarami S, Raiesi O. Mohseni M, et al. Infect Disord Drug Targets. 2022;22(3):e070122200096. doi: 10.2174/1871526522666220107125511. Infect Disord Drug Targets. 2022. PMID: 34994318 Review.
Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortality. The mechanism by which famotidine could improve the outcomes of COVID-19 is currently unknown. A more recent postulated mechanism …
Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortali …
Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp IC. Wesdorp IC. Hepatogastroenterology. 1992 Feb;39 Suppl 1:24-6. Hepatogastroenterology. 1992. PMID: 1577391 Review.
Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD). ...Famotidine is a very useful H2-receptor antagonist for the treatment of most patients with GERD....
Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GER
The association between famotidine and in-hospital mortality of patients with COVID-19.
Kuno T, So M, Takahashi M, Egorova NN. Kuno T, et al. J Med Virol. 2022 Mar;94(3):1186-1189. doi: 10.1002/jmv.27375. Epub 2021 Oct 11. J Med Virol. 2022. PMID: 34609001 Free PMC article.
Famotidine has been considered to be a potential treatment for COVID-19 but the current data is conflicting. ...Famotidine treatment was not associated with a lower risk of in-hospital mortality of COVID-19 patients....
Famotidine has been considered to be a potential treatment for COVID-19 but the current data is conflicting. ...Famotidine tre
Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.
James LP, Kearns GL. James LP, et al. Clin Pharmacokinet. 1996 Aug;31(2):103-10. doi: 10.2165/00003088-199631020-00002. Clin Pharmacokinet. 1996. PMID: 8853932 Review.
Famotidine, an H2 receptor antagonist, has several potential advantages over cimetidine and ranitidine. ...These data support a starting paediatric dosage for intravenous famotidine of 0.5 mg/kg every 8 to 12 hours. In addition, the safety and efficacy of famotid
Famotidine, an H2 receptor antagonist, has several potential advantages over cimetidine and ranitidine. ...These data support a start
The place of famotidine in anti-ulcer therapy.
Mann SG. Mann SG. Aliment Pharmacol Ther. 1987;1 Suppl 1:504S-509S. doi: 10.1111/j.1365-2036.1987.tb00659.x. Aliment Pharmacol Ther. 1987. PMID: 2979698 Review.
Famotidine now presents physicians in the USA and many European countries with a third option when considering H2-antagonist therapy. ...In extensive clinical studies, the adverse effect profile of famotidine is similar to placebo. Famotidine has no known dru
Famotidine now presents physicians in the USA and many European countries with a third option when considering H2-antagonist therapy.
The tolerability and safety profile of famotidine.
Howden CW, Tytgat GN. Howden CW, et al. Clin Ther. 1996 Jan-Feb;18(1):36-54; discussion 35. doi: 10.1016/s0149-2918(96)80177-9. Clin Ther. 1996. PMID: 8851452 Review.
Famotidine is a specific, long-acting histamine2-receptor antagonist. ...Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients worldwide have been treated with famotidine. We present a comprehensive safety pro
Famotidine is a specific, long-acting histamine2-receptor antagonist. ...Since its introduction for the treatment of acid-related dis
2,519 results